Logo

AbCellera Collaborated with Atlas Venture to Discover Therapeutic Antibodies Against Three Drug Targets

Share this
AbCellera Collaborated with Atlas Venture to Discover Therapeutic Antibodies Against Three Drug Targets

AbCellera Collaborated with Atlas Venture to Discover Therapeutic Antibodies Against Three Drug Targets

Shots:

  • AbCellera to receive research fees and will be eligible to receive clinical and commercial milestones along with royalties on net sales of products. The companies collaborated to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company
  • Under the terms of collaboration, Atlas’ portfolio company to get rights to develop and commercialize therapeutic Abs
  • The collaboration will use AbCellera's technology and Atlas' track record of creating an innovative biotechnology company to advance new drug programs more quickly and cost-effectively

Ref: AbCellera | Image: AbCellera

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions